In chemoprevention of head and neck squamous carcinoma (HNSCC), new approaches must consider the sustained epigenetic effects of tobacco use on host molecular mechanisms and identification of novel agents with limited toxicity and acceptable therapeutic ratio. Smoking and nutrition have been identified as significant factors that contribute to carcinogenesis and prognosis of these cancers. Epigenetic CpG island methylation in the tumor promoter gene p16 is frequent in HNSCC and in the mucosa of smokers, premalignant dysplastic tissue and in non-cancerous tissue adjacent to proven malignancies suggesting an important role in early carcinogenesis and second primary malignancy. An important downstream target of p16 that may play a central role in HNSCC carcinogenesis is COX-2. COX-2 over expression is common in premalignant and malignant mucosa and is associated with smoking and chronic inflammation. When blocked, COX-2 decreases tumor growth and invasiveness. COX-2 is influenced by EGFR signaling and p16 inactivation which are commonly perturbed in HNSCC. We propose to identify frequency of gene methylation for p16 and 3 other candidate genes, gene expression alterations and related serum biomarkers associated with clinical outcome using our extensive retrospective tissue and clinical data resource. We will prospectively validate and expand these data and determine specific effects of a tailored smoking cessation program on modulation of identified biomarkers. A Phase II trial is proposed to determine if preoperative soy isoflavones can modulate these markers. Soy isoflavones have been shown to reverse p16 methylation, decrease COX-2 expression and modulate VEGF, IL6, tumor proliferation, angiogenesis and apoptosis. We hypothesize that suppressor gene hypermethvlation in tumor and adjacent non-tumor mucosa and associated molecular changes in downstream targets such as COX-2. VEGF. EGFR and IL6 are associated with clinical outcome and can be abrogated by soy isoflavone supplementation and smoking cessation. We will use pyrosequencing to measure methylation of p16 and three other candidate genes in pretreatment samples from both retrospective and prospective patients and correlate with outcome. We will determine expression of EGFR, COX-2, VEGF, p53 , p65,a6p4 integrin, HPV-16, Bcl-xL in tissue and levels of VEGF, IL6, HGF and 15-Ft2-isoprostane in serial serum and saliva samples from our prospective patients. This comprehensive proposal will investigate the molecular rationale for future soy isoflavone and smoking cessation prevention trials and identify intermediate molecular endpoints. These data will help define high risk patients according to biomarkers and smoking status who might benefit most from chemoprevention. Studies of upregulated gene profiles associated with tumor suppressor gene hypermethylation may identify new target genes for future study.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097248-10
Application #
8382512
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
2014-06-30
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
10
Fiscal Year
2012
Total Cost
$414,405
Indirect Cost
$87,645
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Wolf, Gregory T; Bellile, Emily; Eisbruch, Avraham et al. (2017) Survival Rates Using Individualized Bioselection Treatment Methods in Patients With Advanced Laryngeal Cancer. JAMA Otolaryngol Head Neck Surg 143:355-366
Getz, Kayla R; Rozek, Laura S; Peterson, Lisa A et al. (2017) Family history of cancer and head and neck cancer survival. Laryngoscope 127:1816-1820
Hoban, Connor W; Beesley, Lauren J; Bellile, Emily L et al. (2017) Individualized outcome prognostication for patients with laryngeal cancer. Cancer :
Kim, Hong Sun; Chen, Yu-Chih; Nör, Felipe et al. (2017) Endothelial-derived interleukin-6 induces cancer stem cell motility by generating a chemotactic gradient towards blood vessels. Oncotarget 8:100339-100352
Walline, Heather M; Goudsmit, Christine M; McHugh, Jonathan B et al. (2017) Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines. Head Neck 39:840-852
Kerk, Samuel A; Finkel, Kelsey A; Pearson, Alexander T et al. (2017) 5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 23:2516-2527
Walline, Heather M; Carey, Thomas E; Goudsmit, Christine M et al. (2017) High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. Mol Cancer Res 15:179-188
Udager, A M; McHugh, J B; Goudsmit, C M et al. (2017) Human papillomavirus (HPV) and somatic EGFR mutations are essential, mutually exclusive oncogenic mechanisms for inverted sinonasal papillomas and associated sinonasal squamous cell carcinomas. Ann Oncol :
Gainor, Danielle L; Marchiano, Emily; Bellile, Emily et al. (2017) Survival Outcomes in Patients with T2N0M0 (Stage II) Squamous Cell Carcinoma of the Larynx. Otolaryngol Head Neck Surg 157:625-630
Nör, Felipe; Warner, Kristy A; Zhang, Zhaocheng et al. (2017) Therapeutic Inhibition of the MDM2-p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas. Clin Cancer Res 23:1036-1048

Showing the most recent 10 out of 249 publications